Regeneron Pharmaceuticals Inc $ 579.81 4.08 (0.71%)
REGN News and Headlines - Regeneron Pharmaceuticals Inc
Management's Discussion of Fund Performance1
Economic and Market Conditions
The 12-month period that began September 1, 2019 (the period), included some of the best and worst equity performances in over a decade.
The period began with global equities rallying in the closing months of 2019, supported by interest rate reductions by many central banks worldwide. The previous July, the U.S. Federal Reserve (the Fed) had cut rates for the first time in over a decade, followed by two additional rate cuts in the first two months of the period. By the end of the third quarter of 2019, interest rates
The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiotech. The publication enlisted the help of Jeffries' Jared Holtz to compile a list of the 10 top industry takeover targets.
Holtz thinks that most deals going forward will be those of the mid-size variety. That rules out several companies that were once the most highly coveted but have since become too expensive, including Seattle Genetics Inc. (SGEN), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals Inc. (REGN).
Regeneron Pharmaceuticals (REGN), a U.S.-based biopharmaceutical company, was the top contributor for the fiscal year as management advanced both marketed drugs and their pipeline of new treatments. With regards to marketed drugs, Eylea and Dupixent both continued to increase the number of patients treated for blindness and immune disorders, respectively. In addition, one of Eylea's competitors encountered safety issues, which removed a significant risk to Regeneron. Separately, management advanced potential new treatments for immuno-oncology and rare diseases. They also reacted quickly to the Covid-19 pandemic by developing an antibody treatment for infected patients, which demonstrated initial efficacy. Lastly, management
The Oakmark Global Select Fund returned 1.5% for the fiscal year ended September 30, 2020, underperforming the MSCI World Index, which returned 10.4%. For the most recent quarter, the Fund returned 6.4%, compared to the benchmark's return of 7.9%. More importantly, the Fund has returned an average of 6.7% per year since its inception in October 2006, outperforming the MSCI World Index's annualized gain of 6.1% over the same period.
Regeneron Pharmaceuticals (REGN), a U.S.-based biopharmaceutical company, was the top contributor for the fiscal year as management advanced both marketed drugs and their pipeline of new treatments. With regards to
The Oakmark Select Fund was up 5.2% for the quarter, trailing the S&P 500 Index's 8.9% return. For the fiscal year ending September 30, 2020, the Oakmark Select Fund decreased by 2.5%, compared to a 15.2% gain for the S&P 500 Index. As has been well-documented, this past year has continued a particularly difficult period for value managers; the Russell 1000 Value Index declined by 5.0% over the same 12-month period. We expect no capital gain distribution this year.
The most significant contributors to performance during the quarter were Ally Financial (ALLY) (+28%) and Charter Communications (CHTR) (+22%). For the
The Oakmark Fund increased 6.2% during the third quarter, compared to an 8.9% gain for the S&P 500 Index. For the fiscal year ending September 30, the Oakmark Fund increased 1.2%, trailing the 15.2% gain for the S&P 500. It's only fitting that unusual times produce unexpected outcomes, as illustrated by the fact that just four stocks in the S&P 500 drove approximately 70% of its total return over the past 12 months. Furthermore, the relative underperformance of the Russell 1000 Value Index against the S&P 500 is near an all-time high, with the former down 5% over the past
The Dow Jones Industrial Average closed at 28,425.51 on Thursday with a gain of 122.05 points or 0.43%. The S&P 500 closed at 3,446.83 for a gain of 27.38 points or 0.80%. The Nasdaq Composite closed at 11,420.98 for a gain of 56.38 points or 0.50%. The VIX Volatility Index was lower at 26.36 for a loss of 1.70 points or -6.06%.
Thursday's Market Movers
U.S. indexes posted a second day of closing gains after President Trump retracted comments on fully halting stimulus negotiations. House Speaker Nancy Pelosi says efforts are currently targeting aid for the airline sector.
The Dow Jones Industrial Average closed at 28,148.64 on Monday with a gain of 465.83 points or 1.68%. The S&P 500 closed at 3,408.63 for a gain of 60.19 points or 1.80%. The Nasdaq Composite closed at 11,332.49 for a gain of 257.47 points or 2.32%. The VIX Volatility Index was higher at 27.96 for a gain of 0.33 points or 1.19%.
Monday's Market Movers
Tech stocks led gains for the U.S. indexes Monday. The Nasdaq closed with a gain of 2.32%. The Nasdaq Biotech Index gained 4.26%, led by Myokardia (MYOK), which was up 57.84% after news of an
According to the Historical Data Screen, a new GuruFocus Premium Plus feature, four stocks that have high financial strength and have grown earnings at least 1% every year over the past five years are Check Point Software Technologies Ltd. (CHKP), Grand Canyon Education Inc. (LOPE), MarketAxess Holdings Inc. (MKTX) and Regeneron Pharmaceuticals Inc. (REGN).
New Historical Data Screen feature allows for multiyear data screening
GuruFocus' All-in-One Screener received a new feature where Premium Plus members can screen for stocks for multiple periods at once. Figure 1 illustrates sample Historical Data Screen filters involving
IGM Biosciences, Inc. (IGMS) is one of four health care stocks Jeffries thinks are good buys at the moment, especially for the investor with a higher risk tolerance, according to an article in 24/7 Wall Street.
Given the boost the stock has enjoyed since the brokerage's report came out on Sept.15, shares of the Mountain View, California-based biotech might seem better suited for investors who also have a long-term horizon.
IGM's stock price is up 375% since the company went public a little more than a year ago. It has traded as high as $90 during the past
Investors reacted favorably to the announcement that Chinese biopharmaceutical company Innovent Biologics Inc. (HKSE:01801) and Eli Lilly and Co. (LLY) have expanded their licensing agreement for a cancer drug.
The deal gives Indianapolis-based Eli Lilly the rights to the Tyvyt, which the two have been selling in China for a form of lymphoma. Biopharma Dive reoported Eli Lilly and Innovent had already split rights to the drug based on a 2015 agreement. They'll continue to share the profits under the new deal, but Eli Lilly now obtains rights to Tyvyt everywhere outside of China. Innovent received $200 million upfront from
Managed by Jean Hynes, the fund invests in a variety of health care-related stocks from around the world in order to achieve long-term capital appreciation. She picks stocks of companies that have high-quality balance sheets, strong management teams and the potential for new products that will generate consistently above-average revenue and earnings growth.
Based on these criteria, the fund established holdings in Stryker Corp. (SYK), Royalty Pharma PLC (RPRX) and WuXi Biologics (Cayman) Inc. (HKSE:02269) during
In light of Novavax Inc. (NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (ALXN), Novo Nordisk A/S (NVO), Galapagos NV (GLPG), Regeneron Pharmaceuticals Inc. (REGN) and Vertex Pharmaceuticals Inc. (VRTX).
Novavax continues big surge on coronavirus vaccine federal aid
Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of
Sanofi SA (SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route. Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (BMRN).
Speculation heated up after Sanofi announced it was selling about $11 billion worth of shares it owns in Regeneron Pharmaceuticals Inc. (REGN). That would be a nice down payment, but Sanofi will have to dig deeper into its pockets because Biomarin has a market value of nearly $22 billion. Year to date, its shares are
The Nasdaq Composite Index closed on Wednesday above 10,000 for the first time in history as investors continue their optimistic bet on the economy recovering from the coronavirus-related shutdown. Among the S&P 500 companies trading on the Nasdaq exchange, the five stocks with the largest year-to-date total return are DexCom Inc. (DXCM), Regeneron Pharmaceuticals Inc. (REGN), Nvidia Corp. (NVDA), PayPal Holdings Inc. (PYPL) and Abiomed Inc. (ABMD).
Tech-heavy Nasdaq reaches five-digit intraday high, boosted by Apple and Amazon
Sanofi’s (SNY) decision to hedge its bet on developing a vaccine for Covid-19 has helped nearly double the year-to-date share price of a Boston-area therapeutics company.
Translate Bio Inc.’s (TBIO) partnership with Sanofi builds on the three-year pact the companies signed in June 2018 to use Translate’s technology called mRNA to develop vaccines for up to five infectious diseases. Given the worldwide pandemic, the Covid-19 vaccine is now front and center.
GENE News reported that Translate Bio CEO Ronald C. Renaud Jr. said the companies hope to begin animal testing in weeks. “We have a goal to be in the
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs.
General Mills Inc. reached the 52-week high of $60.67
General Mills (GIS) is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food and ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, Blue Buffalo and Haagen-Dazs.
The price of General Mills Inc. shares has reached $60.67, which is 0.4% off the 52-week high of $60.92. General Mills Inc. has a
As [url=https://www.gurufocus.com/StockBuy.php?GuruName=David+Herro]David Herro[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=David+Herro]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=David+Herro]Portfolio[/url]) wrote in his lead letter, it was a difficult quarter for global markets and the Oakmark Global Select Fund was not exempt. The Fund declined 30.7% for the quarter ended March 31, compared to the MSCI World ex U.S. Index, which lost 21.1%. Since the Fund’s inception in October 2006, it has returned an average of 4.8% per year. The top contributor for both the quarter and the past six months was Regeneron Pharmaceuticals (REGN) (U.S.), while the largest detractor for the same time periods was CNH Industrial (CNHI) (U.K.).
While we are disappointed
Our top contributor in the quarter and over the past six months was Regeneron Pharmaceuticals (REGN). The company is at the forefront of developing potential coronavirus treatments. The relative attractiveness of Regeneron stock has diminished substantially given its strong outperformance, but we still believe the company is selling at a discount to our estimate of its intrinsic value.
From [url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Bill Nygren[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Bill+Nygren]Portfolio[/url])'s Oakmark Select Fund first-quarter 2020 shareholder commentary.
The Oakmark Select Fund was down 33% for the quarter, trailing the S&P 500 Index’s negative 20% return, in a quarter in which the Russell 1000 Value Index underperformed the Russell 1000 Growth Index by 13%. As [url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Bill Nygren[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Bill+Nygren]Portfolio[/url]) pointed out in his quarterly commentary, what started out as a relatively benign quarter turned terrible from late February onwards.
Our top contributor in the quarter and over the past six months was Regeneron Pharmaceuticals (REGN). The company is at the forefront of developing potential coronavirus treatments. The relative attractiveness of Regeneron stock has diminished substantially given its